Sarah Luise Stellnberger

Sarah Luise Stellnberger

Auto-generated profile, based on publicly available information

Sarah Luise Stellnberger

Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, Vienna 1090, Austria; Vienna Doctoral School of Pharmaceutical, Nutritional and Sport Sciences (VDS PhaNuSpo), Vienna 1090, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
CSClemens P. Spielvogel
Clemens P. Spielvogel
NSNatalie Schindler
Natalie Schindler
CSChristian Schröder
Christian Schröder
SSSarah Luise Stellnberger
Sarah Luise Stellnberger
Wolfgang WadsakWolfgang Wadsak
Wolfgang Wadsak
CVChrysoula Vraka
Chrysoula Vraka
Predicting blood-brain barrier (BBB) penetration is crucial for developing central nervous system (CNS) drugs, representing a significant hurdle in successful clinical phase I studies. One of the most valuable properties for this prediction is the polar surface area (PSA). However, molecular structures are missing geometric optimization, which, together with lack of standardization, leads to variations in calculation. Additionally, prediction rules have been established by combining different molecular properties such as the BBB score or CNS multiparameter optimization (CNS MPO). This study aims to create an approach for 3D PSA calculation, to directly apply this value in combination with a set of 23 other parameters in a novel machine learning (ML)-based scoring, and to further evaluate existing prediction models using a standardized database. We developed and analyzed a standardized data set derived from the same laboratory, encompassing 24 calculated and experimentally determined molecular parameters such as PSA from various models, HPLC log P values, and hydrogen bond characteristics for 154 radiolabeled molecules and licensed or well-characterized drugs. These molecules were classified into categories based on BBB penetration, nonpenetration, and interactions with efflux transporters. We supplemented these with a novel in silico 3D calculation of nonclassical PSA. Additionally, we have calculated published prediction rules based on this standardized and transparent database. Using these data, we trained various ML models within a 100-fold Monte Carlo cross-validation framework to derive a novel ML-based prediction score for BBB penetration and validated the three most used existing predictive rules. To interpret the influence of individual molecular parameters and different existing predictive rules, we employed explainable artificial intelligence methods including Shapley additive explanations (SHAP) and surrogate modeling. The ML approach outperformed existing scores for BBB penetration by applying a complex nonlinear integration of molecular properties, with the random forest model achieving the best performance for predicting binary BBB penetration (area under the receiver operating characteristic curve (AUC) 0.88, 95% confidence intervals: 0.87-0.90), and multiclass efflux transporter versus CNS-positive and CNS-negative prediction (AUC 0.82, 95% CI: 0.81-0.82). SHAP analysis revealed the multifactorial nature of the problem, highlighting the advantage of multivariate models over single predictive parameters. The ML model's superior predictive capability was demonstrated in comparison with existing scoring systems, like the CNS MPO (AUC 0.53), the CNS MPO Positron emission tomography (PET) (AUC 0.51), and BBB score (AUC 0.68) while also enabling the identification of efflux transporter substrates and inhibitors. Our integrated ML approach, combining experimental and in silico measurements with novel in silico methods based on a standardized database including a plethora of different substance groups (licensed drugs and in vivo evaluated PET tracers), enhances the prediction of BBB penetration. This approach may reduce the reliance on extensive experimental measurements and animal testing, accelerating CNS drug development.

22 April 2025 in Journal of Hazardous Materials
Verified
Journal Article
Open access
LKLukas Kogler
Lukas Kogler
SSSarah Stellnberger
Sarah Stellnberger
VSVerena Schwingenschlögl-Maisetschläger
Verena Schwingenschlögl-Maisetschläger
LALisa Aichinger
Lisa Aichinger
VKVerena Kopatz
Verena Kopatz
VPVerena Pichler
Verena Pichler
Microplastics comprise a heterogeneous group of polymer particles that vary in chemical properties, size, and shape, that may influence their environmental and in vivo behavior. Numerous in vitro and in vivo studies show induction of oxidative stress and metabolic disturbances. Valid critique regarding unrealistically high concentrations or additives within standard materials calls some results into question. Here, we present a novel protocol for the detergent-free production of polyethylene terephthalate (PET) and biodegradable poly(butylenadipat-co-terephthalat) (PBAT) micro- and nanoplastic particles (MNPs) as model microplastics for research. The particles were produced by dissolution precipitation from trifluoroacetic acid (TFA) for PET or tetrahydrofuran (THF)/ethanol for PBAT. Different PET sources were investigated for MNPs production. PET MNPs in the size range of 170-1000 nm with up to 80 % yield were produced from pellets as starting material. Particle size can be adjusted by ultrasounding. The non-toxic concentration range for two commonly used detergents was assessed by means of MTT assay. PET particles with a Zeta-potential of -45 were stable in aqueous suspension with and without detergents at neutral pH. Biodegradable PBAT particles in the micro- and nanometer range were produced by adapting the PET precipitation protocol. These high-yield production protocols provide additive-free authentic PET and PBAT MNPs for research.